Viewing Study NCT05657158

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:00 AM
Ignite Modification Date: 2026-02-23 @ 8:07 PM
Study NCT ID: NCT05657158
Status: COMPLETED
Last Update Posted: 2022-12-20
First Post: 2022-11-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Intraocular Inflammation View
None Retinal Vascular Occlusion View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Brolucizumab View
None Neovascular age-related macular degeneration View
None occlusive retinal vasculitis View
None retinal vasculitis View
None RV View
None retinal vascular occlusion View
None RO View
None ocular images View